Samsung announces acquisition of Sonio to strengthen its leadership position in advanced medical devices

Samsung Medison, a global medical equipment company and subsidiary of Samsung Electronics, today announced that it has signed an agreement to acquire 100% of the shares of Sonio SAS, an AI software company for fetal ultrasound.

Founded in 2020 to improve the health of women and children around the world through medical advancements, Sonio has developed IT solutions and AI assistant features for obstetrics and gynecology ultrasound that help healthcare professionals evaluate and document ultrasound examinations.

Sonio Detect, an FDA-cleared 510(k) AI assistant, leverages deep learning networks to ensure better image quality in real-time and improve quality of care through greater clinical accuracy.

Following the completion of the transaction, Sonio will remain an independent company headquartered in France and will continue its commercial growth independently while its products and services will remain compatible with all ultrasound device manufacturers.

Combined with Sonio’s world-class AI expertise, Samsung Medison’s cutting-edge ultrasound systems will help commercialize revolutionary AI-enhanced workflows and accelerate innovation in patient outcomes and quality of prenatal care.

“We have great respect and admiration for what the Sonio team has built in maternal care. Through the acquisition of Sonio, Samsung Medison will continue to deliver on its promise of improving people’s quality of life through technology,” said Yong Kwan Kim, CEO of Samsung Medison. “The collaboration with Sonio will bring together best-in-class ultrasound AI technology and reporting capabilities to bring a paradigm shift in prenatal ultrasound examination. »

“Samsung Medison’s established global ultrasound business, combined with Sonio’s advanced AI, creates an exciting growth opportunity for both parties,” said Cécile Brosset, CEO of Sonio. “In Samsung Medison, we have found a great and trusted partner to continue and accelerate our roadmap and mission. In addition to its close collaboration with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software globally, including for underserved areas of healthcare.

Completion of the transaction is subject to applicable regulatory approvals, including the approval of the French Ministry of Economy and Finance.

About Samsung Médison
Samsung Medison is a leader global medical device company, specializing in diagnostic imaging devices. With a mission to bring health and well-being into people’s lives, the company is committed to creating a new future for healthcare professionals and patients around the world in various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating the world’s best technologies in computing, image processing, semiconductors and communications into medical devices. For more information, please visit https://www.samsungmedison.com/

About Sonio
Sonio’s AI-enhanced software empowers and helps prenatal sonographers and ultrasound readers perform prenatal exams that meet the highest quality standards, while ensuring the completeness of each exam, streamlining their workflow and increasing the accuracy of prenatal diagnostics. Sonio’s software is the result of more than five years of research and collaboration between leading experts in the fields of maternal-fetal medicine and AI. Sonio’s investors include Elaia Partners, Bpifrance’s French Tech Seed fund, OneRagtime, Cross Border Impact Ventures and the EIC (European Innovation Council) fund. To learn more about Sonio, visit our website https://sonio.ai/